Login Register Cart 0
Generic placeholder image

Current Molecular Medicine

Editor-in-Chief

ISSN (Print): 1566-5240
ISSN (Online): 1875-5666

Back
Journal Home About Journal Editorial Board Journal Insight Current Issue Volumes/Issues
Subscribe
Research Article

Chronic Administration of Methamphetamine Aggravates Atherosclerotic Vulnerable Plaques in Apolipoprotein E Knockout Mice Fed with a High-cholesterol Diet

Author(s): Xiaoxue Cui, Bo Gao, Yijun Yu, Ye Gu and Liqun Hu*

Volume 24, Issue 4, 2024

Published on: 18 May, 2023

Page: [495 - 504] Pages: 10

DOI: 10.2174/1566524023666230321095233

Price: $65

Abstract

Background: It has been observed previously that chronic methamphetamine (METH) administration could upregulate neuropeptide Y (NPY) expression and promote atherosclerotic formation in apolipoprotein E knockout (ApoE-/-) mice fed with a normal cholesterol or high diet and NPY might be involved in the pathogenesis of METHinduced atherogenic effects through NPY Y1 receptor pathway. Vulnerable coronary atherosclerotic plaque (VP) is a critical pathological finding responsible for the acute coronary syndrome (ACS). In this study, we explored whether METH abuse could aggravate the formation of VP in ApoE-/- mice fed with high cholesterol diet.

Objective: The purpose of this study was to observe if chronic METH administration could aggravate vulnerable plaque (VP) formation in ApoE-/- mice fed with a highcholesterol diet.

Methods: Male ApoE-/- mice fed with a high-cholesterol diet were intraperitoneally injected with normal saline (NS) or 8 mg/kg/day METH (M8) for 24 weeks. Body weight was monitored from baseline to 24 weeks at 2 weeks intervals. After 24 weeks of treatment, plasma lipid variables were measured. Movat's staining and immunohistochemical staining were performed on frozen sections of the aortic roots to calculate VP percentage and intraplaque hemorrhage (IPH) percentage and detect expression of NPY, vascular endothelial growth factor (VEGF), and CD31. In vitro, the expressions of Y2R, VEGF, and CD31 were detected by immunofluorescence staining in aortic endothelial cells incubated with PBS, 100μM METH, 10nmol NPY, or 100μM METH plus 10nmol NPY for 12 hours.

Results: The CD31 positive area, percentage of IPH, VP, and the expressions of NPY and VEGF were significantly increased in the M8 group than in the NS group. In vitro, the expressions of Y2R, VEGF, and CD31 were significantly increased in the METH+NPY group than in the PBS, METH, and NPY groups and these effects could be blunted by treatment with a Y2R antagonist or DPPIV inhibitor.

Conclusion: Chronic METH administration could aggravate VP in ApoE-/- mice fed with a high-cholesterol diet, possibly through upregulating vascular NPY and VEGF expression and promoting angiogenesis and vessel rupture in atherosclerotic plaques. Our findings indicated that increased VP formation might contribute to the development of acute coronary syndrome post-chronic METH abuse by activating DPPIV/NPY/Y2R pathway.

« Previous Next »
[1]
Kaye S, Darke S, Duflou J, McKetin R. Methamphetamine-related fatalities in Australia: Demographics, circumstances, toxicology and major organ pathology. Addiction 2008; 103(8): 1353-60.
[http://dx.doi.org/10.1111/j.1360-0443.2008.02231.x] [PMID: 18855825]
[2]
Turnipseed SD, Richards JR, Kirk JD, Diercks DB, Amsterdam EA. Frequency of acute coronary syndrome in patients presenting to the Emergency Department with chest pain after methamphetamine use. J Emerg Med 2003; 24(4): 369-73.
[http://dx.doi.org/10.1016/S0736-4679(03)00031-3] [PMID: 12745036]
[3]
Gao B, Li L, Zhu P, et al. Chronic administration of methamphetamine promotes atherosclerosis formation in ApoE−/− knockout mice fed normal diet. Atherosclerosis 2015; 243(1): 268-77.
[http://dx.doi.org/10.1016/j.atherosclerosis.2015.09.001] [PMID: 26409626]
[4]
Zhu P, Li L, Gao B, et al. Impact of chronic methamphetamine treatment on the atherosclerosis formation in ApoE−/− mice fed a high cholesterol diet. Oncotarget 2017; 8(33): 55064-72.
[http://dx.doi.org/10.18632/oncotarget.19020] [PMID: 28903402]
[5]
Gonçalves J, Baptista S, Olesen MV, et al. Methamphetamine-induced changes in the mice hippocampal neuropeptide Y system: implications for memory impairment. J Neurochem 2012; 123(6): 1041-53.
[http://dx.doi.org/10.1111/jnc.12052] [PMID: 23061411]
[6]
Lagraauw HM, Westra MM, Bot M, et al. Vascular neuropeptide Y contributes to atherosclerotic plaque progression and perivascular mast cell activation. Atherosclerosis 2014; 235(1): 196-203.
[http://dx.doi.org/10.1016/j.atherosclerosis.2014.04.025] [PMID: 24858338]
[7]
Li L, Najafi AH, Kitlinska JB, et al. Of mice and men: Neuropeptide Y and its receptors are associated with atherosclerotic lesion burden and vulnerability. J Cardiovasc Transl Res 2011; 4(3): 351-62.
[http://dx.doi.org/10.1007/s12265-011-9271-5] [PMID: 21468772]
[8]
Hirsch D, Zukowska Z. NPY and stress 30 years later: The peripheral view. Cell Mol Neurobiol 2012; 32(5): 645-59.
[http://dx.doi.org/10.1007/s10571-011-9793-z] [PMID: 22271177]
[9]
Segal DS, Kuczenski R, O’Neil ML, Melega WP, Cho AK. Escalating dose methamphetamine pretreatment alters the behavioral and neurochemical profiles associated with exposure to a high-dose methamphetamine binge. Neuropsychopharmacology 2003; 28(10): 1730-40.
[http://dx.doi.org/10.1038/sj.npp.1300247] [PMID: 12865898]
[10]
Najafi AH, Aghili N, Tilan JU, et al. A new murine model of stress-induced complex atherosclerotic lesions. Dis Model Mech 2013; 6(2): dmm.009977.
[http://dx.doi.org/10.1242/dmm.009977] [PMID: 23324329]
[11]
Vendrov AE, Stevenson MD, Alahari S, et al. Attenuated superoxide dismutase 2 activity induces atherosclerotic plaque instability during aging in hyperlipidemic mice. J Am Heart Assoc 2017; 6(11): e006775.
[http://dx.doi.org/10.1161/JAHA.117.006775] [PMID: 29079564]
[12]
Chen F, Zhou Y, Yang K, Shen M, Wang Y. NPY stimulates cholesterol synthesis acutely by activating the SREBP2-HMGCR pathway through the Y1 and Y5 receptors in murine hepatocytes. Life Sci 2020; 262: 118478.
[http://dx.doi.org/10.1016/j.lfs.2020.118478] [PMID: 32976883]
[13]
Zhu P, Sun W, Zhang C, Song Z, Lin S. The role of neuropeptide Y in the pathophysiology of atherosclerotic cardiovascular disease. Int J Cardiol 2016; 220: 235-41.
[http://dx.doi.org/10.1016/j.ijcard.2016.06.138] [PMID: 27389447]
[14]
Bruinstroop E, Pei L, Ackermans MT, et al. Hypothalamic neuropeptide Y (NPY) controls hepatic VLDL-triglyceride secretion in rats via the sympathetic nervous system. Diabetes 2012; 61(5): 1043-50.
[http://dx.doi.org/10.2337/db11-1142] [PMID: 22461566]
[15]
Della-Morte D, Dong C, Crisby M, et al. Association of carotid plaque morphology and glycemic and lipid parameters in the northern manhattan study. Front Cardiovasc Med 2022; 9: 793755.
[http://dx.doi.org/10.3389/fcvm.2022.793755] [PMID: 35141303]
[16]
Fonseca FAH, de Oliveira Izar MC. High-sensitivity C-reactive protein and cardiovascular disease across countries and ethnicities. Clinics 2016; 71(4): 235-42.
[http://dx.doi.org/10.6061/clinics/2016(04)11] [PMID: 27166776]
[17]
Hu S, Liu Y, You T, Zhu L. Semaphorin 7A promotes VEGFA/VEGFR2-mediated angiogenesis and intraplaque neovascularization in ApoE-/- mice. Front Physiol 2018; 9: 1718.
[http://dx.doi.org/10.3389/fphys.2018.01718] [PMID: 30555351]
[18]
Lee EW, Michalkiewicz M, Kitlinska J, et al. Neuropeptide Y induces ischemic angiogenesis and restores function of ischemic skeletal muscles. J Clin Invest 2003; 111(12): 1853-62.
[http://dx.doi.org/10.1172/JCI16929] [PMID: 12813021]
[19]
Ventura F, Muga M, Coelho-Santos V, Fontes-Ribeiro CA, Leitão RA, Silva AP. Protective effect of neuropeptide Y2 receptor activation against methamphetamine-induced brain endothelial cell alterations. Toxicol Lett 2020; 334: 53-9.
[http://dx.doi.org/10.1016/j.toxlet.2020.09.013] [PMID: 32956829]
[20]
Movafagh S, Hobson JP, Spiegel S, et al. Neuropeptide Y induces migration, proliferation, and tube formation of endothelial cells bimodally via Y1, Y2, and Y5 receptors. FASEB J 2006; 20(11): 1924-6.
[http://dx.doi.org/10.1096/fj.05-4770fje] [PMID: 16891622]
[21]
Kolodgie FD, Gold HK, Burke AP, et al. Intraplaque hemorrhage and progression of coronary atheroma. N Engl J Med 2003; 349(24): 2316-25.
[http://dx.doi.org/10.1056/NEJMoa035655] [PMID: 14668457]
[22]
Virmani R, Kolodgie FD, Burke AP, et al. Atherosclerotic plaque progression and vulnerability to rupture: Agiogenesis as a source of intraplaque hemorrhage. Arterioscler Thromb Vasc Biol 2005; 25(10): 2054-61.
[http://dx.doi.org/10.1161/01.ATV.0000178991.71605.18] [PMID: 16037567]
[23]
Chistiakov DA, Orekhov AN, Bobryshev YV. Contribution of neovascularization and intraplaque haemorrhage to atherosclerotic plaque progression and instability. Acta Physiol 2015; 213(3): 539-53.
[http://dx.doi.org/10.1111/apha.12438] [PMID: 25515699]
[24]
Parma L, Baganha F, Quax PHA, de Vries MR. Plaque angiogenesis and intraplaque hemorrhage in atherosclerosis. Eur J Pharmacol 2017; 816: 107-15.
[http://dx.doi.org/10.1016/j.ejphar.2017.04.028] [PMID: 28435093]
[25]
Michel JB, Thaunat O, Houard X, Meilhac O, Caligiuri G, Nicoletti A. Topological determinants and consequences of adventitial responses to arterial wall injury. Arterioscler Thromb Vasc Biol 2007; 27(6): 1259-68.
[http://dx.doi.org/10.1161/ATVBAHA.106.137851] [PMID: 17395854]
[26]
Michel JB, Martin-Ventura JL, Nicoletti A, Ho-Tin-Noé B. Pathology of human plaque vulnerability: Mechanisms and consequences of intraplaque haemorrhages. Atherosclerosis 2014; 234(2): 311-9.
[http://dx.doi.org/10.1016/j.atherosclerosis.2014.03.020] [PMID: 24726899]

Rights & Permissions Print Cite
© 2024 Bentham Science Publishers | Privacy Policy